Aldeyra Therapeutics to Participate in Upcoming Investor Conferences

Aldeyra Therapeutics, Inc. ALDX (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will participate in the following investor conferences in September:

• Citi's 14^th Annual Biotech Conference
  
  Four Seasons Hotel
  
  Boston, Mass.
  
  Thursday, September 5, 2019
  
  
• BioCentury 26th Annual NewsMakers in the Biotech Industry
  
  Millennium Times Square New York
  
  New York, N.Y.
  
  Friday, September 6, 2019
  
  
• 3rd Annual Janney Healthcare Conference
  
  The Union League Club
  
  New York, N.Y.
  
  Monday, September 9, 2019
  
  Presentation time: 11:50 a.m. ET
  
  

The Janney presentation will be webcast live and archived on the "Investors" section of the Aldeyra website, http://ir.aldeyra.com/.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead investigational drug product candidates are first-in-class potential treatments in development for dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for retinal and systemic inflammatory diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190828005400/en/